Search
DE EN
more info

Contact:
Phone:+49 0761 1514 440 Fax:+49 0761 1514 460 Email: info[at]falkfoundation.org

Falk Gastro Review Journal

Current science, compiled for you from the multitude of scientific publications – this is the Falk Gastro Review Journal.

Dunkel- bis hellblaue Grafik einer Tonspur-Frequenz auf orangem Hintergund.

The latest issues

Edition 2/2025

Edition 1/2025

Edition 4/2024

Find here all FGR publications since mid-2022 selected and reviewed from international medical journals. Click here above to browse the individual quarterly issues or use the filters below or click chronologically through all articles.

All articles

Colon to Rectum

Sex-related differences in the phenotype and course of inflammatory bowel disease: SEXEII study of ENEIDA

Gargallo-Puyuelo CJ, Ricart E, Iglesias E, de Francisco R, Gisbert JP, Taxonera C, Mañosa M, Aguas Peris M, Navarrete-Muñoz EM, Sanahuja A, Guardiola J, Mesonero F, Rivero Tirado M, Barrio J, Vera Mendoza I, de Castro Parga L, García-Planella E, Calvet X, Martín Arranz MD, García S, Sicilia B, Carpio D, Domenech E, Gomollón F; ENEIDA registry of GETECCU

Colon to Rectum

Phase 2 trial of anti-TL1A monoclonal antibody tulisokibart for ulcerative colitis

N Engl J Med. 2024;391(12):1119–29

With expert opinion

Sands BE, Feagan BG, Peyrin-Biroulet L, Danese S, Rubin DT, Laurent O, Luo A, Nguyen DD, Lu J, Yen M, Leszczyszyn J, Kempiński R, McGovern DPB, Ma C, Ritter TE, Targan S; ARTEMIS-UC Study Group

Colon to Rectum

Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): An open-label, multicentre, randomised controlled trial

Lancet Gastroenterol Hepatol. 2024;9(11):981–96

Choy MC, Li Wai Suen CFD, Con D, Boyd K, Pena R, Burrell K, Rosella O, Proud D, Brouwer R, Gorelik A, Liew D, Connell WR, Wright EK, Taylor KM, Pudipeddi A, Sawers M, Christensen B, Ng W, Begun J, Radford-Smith G, Garg M, Martin N, van Langenberg DR, Ding NS, Beswick L, Leong RW, Sparrow MP, De Cruz P

Colon to Rectum

Comparative risk of serious infection with vedolizumab versus anti-tumor necrosis factor in inflammatory bowel disease: Results from nationwide Swedish registers

Am J Gastroenterol. 2024;119(12):2480-2492

Karlqvist S, Sachs MC, Eriksson C, Cao Y, Montgomery S, Ludvigsson JF, Olén O, Halfvarson J; SWIBREG Study Group

Colon to Rectum

Preterm birth and in utero exposure to corticosteroids are associated with increased infection risk in children of mothers with IBD

Inflamm Bowel Dis. 2024;30(12):2297-2305

Vestergaard T, Holm Meiltoft I, Julsgaard M, Bek Helmig R, Friedman S, Kelsen J

Colon to Rectum

Extended induction and prognostic indicators of response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials

Inflamm Bowel Dis. 2024;30(12):2335-2346

D’Haens G, Higgins PDR, Peyrin-Biroulet L, Sands BE, Lee S, Moses RE, Redondo I, Escobar R, Hunter Gibble T, Keohane A, Morris N, Zhang X, Arora V, Kobayashi T

Colon to Rectum

A multicenter randomized controlled trial of microbiome-based artificial intelligence-assisted personalized diet versus low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet: A novel approach for the management of irritable bowel syndrome

Am J Gastroenterol. 2024;119(9):1901-1912

Tunali V, Arslan NÇ, Ermiş BH, Derviş Hakim G, Gündoğdu A, Hora M, Nalbantoğlu ÖU

Colon to Rectum

Clinical trial: Effects of treatment with a vibrating capsule in patients with severe chronic constipation

Aliment Pharmacol Ther. 2024;60(7):855-862

Lembo A, Simons M, Loesch J, Hamza E, Graff EL, Quigley E, Rao SSC

Colon to Rectum

The efficacy of tradipitant in patients with diabetic and idiopathic gastroparesis in a phase 3 randomized placebo-controlled clinical trial

Clin Gastroenterol Hepatol. 2024;22(12):2506-2516

Carlin JL, Polymeropoulos C, Camilleri M, Lembo A, Fisher M, Kupersmith C, Madonick D, Moszczynski P, Smieszek S, Xiao C, Birznieks G, Polymeropoulos MH